Nomura Y
Gan. 1976 Oct;67(5):703-11.
The estrogen receptor was assayed, using the 2,000g supernatant and dextran-coated charcoal method, in 243 tissue samples from human breast cancer, benign breast diseases, macroscopically normal breast tissues, normal uterine myometrium, and uterine myoma. The estrogen receptor was found to be positive in 52.1% of 98 primary breast cancer and in 54.1% of 24 metastatic tumors. The receptor in the breast cancer was found to be similar to that in normal uterine myometrium in the binding character; that is, the dissociation constant of 10(-9) approximately 10(-11) M and number of binding sites of 0 approximately 2,800 fmol/mg protein. There was no correlation between the presence of the receptor and some clinical factors such as menopausal status, age of the patient, urinary 17-ketosteroid excretion, clinical stage of cancer, tumor size, positive or negative axillary lymph node metastasis, histological type, metastatic site of the cancer, or disease-free interval. The estrogen receptor appeared to be retained by metastasis of cancer, and this may lead to the use of the receptor assay with mastectomy specimens for the prediction of response to hormonal therapy in future recurrence of malignancy. Furthermore, it may be possible by this assay to select patients suitable for adjuvant therapy with hormones at the time of mastectomy. A good correlation was found between the presence of the receptor and response to the major endocrine ablation therapy in patients with advanced or metastatic breast cancer. When the receptor was negative in the cancer tissue, the change of response to the endocrine therapy was minimum. On the other hand, if the cancer contained the receptor, approximately 60% of the patients with metastatic or advanced breast cancer responded well to the major endocrine ablation therapy. Thus, the estrogen receptor of breast cancer in Japanese patients appears to bear a close resemblance to that reported in Western patients in its incidence and the correlation to some biological characteristics of the cancer.
采用2000g上清液和葡聚糖包被活性炭法，对来自人乳腺癌、乳腺良性疾病、大体正常乳腺组织、正常子宫肌层及子宫肌瘤的243份组织样本进行雌激素受体检测。在98例原发性乳腺癌中，52.1%雌激素受体呈阳性；在24例转移性肿瘤中，54.1%雌激素受体呈阳性。发现乳腺癌中的受体在结合特性上与正常子宫肌层中的受体相似，即解离常数为10(-9)～10(-11)M，结合位点数为0～2800fmol/mg蛋白。受体的存在与一些临床因素之间无相关性，如绝经状态、患者年龄、尿17-酮类固醇排泄量、癌症临床分期、肿瘤大小、腋窝淋巴结转移阳性或阴性、组织学类型、癌症转移部位或无病生存期。雌激素受体似乎可通过癌症转移而保留，这可能导致在未来恶性肿瘤复发时，对乳房切除标本进行受体检测以预测对激素治疗的反应。此外，通过该检测有可能在乳房切除时选择适合激素辅助治疗的患者。在晚期或转移性乳腺癌患者中，发现受体的存在与对主要内分泌消融治疗的反应之间存在良好相关性。当癌组织中受体为阴性时，内分泌治疗反应的变化最小。另一方面，如果癌组织含有受体，约60%的转移性或晚期乳腺癌患者对主要内分泌消融治疗反应良好。因此，日本患者乳腺癌的雌激素受体在发生率及其与癌症某些生物学特征的相关性方面，似乎与西方患者报道的情况极为相似。
